Blia Vang
Family · Houston, TXNPI 1427161389
Payments from drug & device makers
Across 332 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$981
- Almatica Pharma LLC$628
- AbbVie$589
- Takeda Pharmaceuticals U.S.A., Inc.$547
- Alkermes, Inc.$478
- Lundbeck LLC$410
- plus $3K from 18 others
What the payments were for
- Food & beverage$6,48199%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 41 | $981 |
| Almatica Pharma LLC | 32 | $628 |
| AbbVie | 40 | $589 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $547 |
| Alkermes, Inc. | 20 | $478 |
| Lundbeck LLC | 21 | $410 |
| Neurocrine Biosciences, Inc. | 19 | $403 |
| Sunovion Pharmaceuticals Inc. | 17 | $400 |
| Corium, LLC | 23 | $344 |
| Bausch Health US, LLC | 17 | $286 |
| Teva Pharmaceuticals USA, Inc. | 15 | $280 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $229 |
| Vanda Pharmaceuticals Inc. | 10 | $178 |
| Validus Pharmaceuticals LLC | 4 | $124 |
| Axsome Therapeutics, Inc. | 5 | $99 |
| Eisai Inc. | 6 | $94 |
| Ironshore Pharmaceuticals Inc. | 4 | $85 |
| Tris Pharma Inc | 4 | $79 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| Noven Therapeutics, LLC | 3 | $59 |
| Johnson & Johnson | 2 | $57 |
| Neos Therapeutics, LP | 3 | $50 |
| Adlon Therapeutics L.p. | 2 | $38 |
| Alfasigma USA, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$122
How this compares
$6,528 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 13 | $759 |
| Clonazepam | 26 | $296 |
| Sertraline Hcl | 14 | $55 |
| Diazepam | 21 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $628 | $5514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.